ÂÜÀòÂÒÂ×

Dr. Carmi has completed his Ph.D. studies summa cum laude, at the Department of Immunology at Ben Gurion University, and won a number of excellence awards for his work on the interactions between inflammation and cancer.

He then worked as a post-doctorate fellow under the supervision of Edgar Engelman at Stanford University, where they published their breakthrough work on dendritic cell vaccine in cancer. This work laid the theoretical foundations for establishing Bolt Biotherapeutics (BOLT), in which he was one of the co-inventors and scientific co-founders.

Since 2016 Dr. Carmi heads his own research group at the Department of Pathology at Tel-Aviv University. His lab focuses on the interactions between the immune system and tumor cells and on finding new ways to harness their cytotoxic abilities to fight cancer. One of their discoveries was a novel subset of T cells expressing a receptor for antibodies that can mediate tumor cell killing. Based on this discovery he co-founded Gilboa Therapeutics. Dr. Carmi has served as a consultant for tumor immunology for several companies, including Velocity Pharmaceutical Development, and X-37. He filled five patents and published over 37 peer-review papers including in Nature and Cell as a first author, all in the field of tumor immunology.